Relmada Therapeutics, Inc. (NASDAQ:RLMD) Expected to Post Earnings of -$1.21 Per Share

Wall Street brokerages expect that Relmada Therapeutics, Inc. (NASDAQ:RLMDGet Rating) will post earnings per share (EPS) of ($1.21) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Relmada Therapeutics’ earnings. The lowest EPS estimate is ($1.26) and the highest is ($1.12). Relmada Therapeutics reported earnings per share of ($1.34) during the same quarter last year, which would suggest a positive year-over-year growth rate of 9.7%. The company is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Relmada Therapeutics will report full-year earnings of ($5.15) per share for the current financial year, with EPS estimates ranging from ($5.25) to ($4.97). For the next year, analysts expect that the firm will post earnings of ($3.76) per share, with EPS estimates ranging from ($5.67) to ($2.50). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that cover Relmada Therapeutics.

Relmada Therapeutics (NASDAQ:RLMDGet Rating) last issued its quarterly earnings results on Wednesday, March 23rd. The company reported ($1.80) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.20). During the same period in the previous year, the company posted ($1.28) EPS.

Several analysts have issued reports on RLMD shares. The Goldman Sachs Group cut their price objective on Relmada Therapeutics from $69.00 to $53.00 and set a “buy” rating on the stock in a report on Thursday, March 24th. SVB Leerink decreased their target price on shares of Relmada Therapeutics from $50.00 to $42.00 and set an “outperform” rating for the company in a research note on Monday, December 20th. Finally, Zacks Investment Research upgraded shares of Relmada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 26th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from, Relmada Therapeutics currently has an average rating of “Buy” and an average target price of $38.11.

Relmada Therapeutics stock traded down $0.33 during midday trading on Tuesday, hitting $25.07. The company’s stock had a trading volume of 113,245 shares, compared to its average volume of 296,002. The business’s 50-day simple moving average is $22.40. Relmada Therapeutics has a 12 month low of $16.23 and a 12 month high of $40.00. The firm has a market capitalization of $737.89 million, a P/E ratio of -3.51 and a beta of 0.45.

In other Relmada Therapeutics news, Director Paul Edward Kelly sold 10,000 shares of the firm’s stock in a transaction on Monday, April 4th. The shares were sold at an average price of $30.04, for a total value of $300,400.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 11.00% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Byrne Asset Management LLC boosted its position in Relmada Therapeutics by 15.1% during the 1st quarter. Byrne Asset Management LLC now owns 6,675 shares of the company’s stock worth $180,000 after acquiring an additional 875 shares during the last quarter. apricus wealth LLC bought a new stake in Relmada Therapeutics in the 4th quarter valued at $765,000. Norges Bank bought a new stake in Relmada Therapeutics in the 4th quarter valued at $2,219,000. Walleye Capital LLC bought a new position in Relmada Therapeutics during the 4th quarter worth $469,000. Finally, BlackRock Inc. increased its position in Relmada Therapeutics by 14.5% during the 4th quarter. BlackRock Inc. now owns 1,385,235 shares of the company’s stock worth $31,211,000 after buying an additional 174,994 shares during the period. 52.89% of the stock is owned by institutional investors.

Relmada Therapeutics Company Profile (Get Rating)

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults.

Featured Articles

Get a free copy of the Zacks research report on Relmada Therapeutics (RLMD)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Relmada Therapeutics (NASDAQ:RLMD)

Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with's FREE daily email newsletter.